- Virtus Health (VRT) has appointed Kate Munnings as the new CEO
- Previously, Kate was the Chief Operating Officer at Ramsay Health Care
- Kate will be taking Sue Channon’s position, who will leave at the end of February, however, Kate will be starting her role in early May
- During that time the current Chief Financial Officer, Glenn Powers will fill in as the CEO
- Virtus Health is up 3.23 per cent at market close, trading at $4.47 per share
Major in vitro fertilisation provider Virtus Health (VRT) has appointed Kate Munnings as the new Chief Executive Officer.
Previously, Kate was the Chief Operating Officer at Ramsay Health Care. In that role, she led the operational performance of the Australian organisation which included 73 public and private hospitals.
She has experience working alongside specialist doctors and the company believes she is well equipped to lead Virtus Health.
Prior to working with Ramsay Health Care, Kate was the CEO at Transfield Services which is now known as Broadspectrum. In this position, she led the Logistics, Construction & Consulting business which provided services to State and Commonwealth Government agencies across Australia and internationally.
Kate has demonstrated a successful track record leading commercial improvement,
organisational and business transformation across multiple sectors & industries,” the company said.
“To work with the talented people across 43 fertility clinics in five countries; an Australian network of general pathology, specialist fertility and genetic testing services and seven-day hospitals, helping couples and single women achieve their aspirations to create a family,” Kate said.
“Virtus Health, as one of the first publicly listed fertility businesses in the world, has great opportunities ahead to leverage a significant global footprint and its
diversified services,” she added.
Kate will be taking Sue Channon’s position, who will leave at the end of February.
As Kate will be starting her role on May 4, the current Chief Financial Officer, Glenn Powers, will fill in as the CEO between the transition.
“I would like to thank Sue Channon for her contribution to the development of Virtus Health as its inaugural Group Chief Executive Officer since listing in 2013,” Sonia Petering said.
“Sue is held in the highest regard by our fertility specialists, professional staff and the ARS industry globally. We wish Sue well for her future,” she added.
Virtus Health is up 3.23 per cent on market close, trading at $4.47 per share.